Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.05 USD | -2.13% | +1.61% | -60.39% |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
May. 16 | UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-60.39% | 313M | C- | ||
+75.56% | 12.56B | B- | ||
-23.35% | 7.47B | C+ | ||
+8.51% | 6.75B | C- | ||
+14.95% | 5.5B | D+ | ||
-14.65% | 4.94B | B | ||
+30.59% | 4.66B | - | ||
-25.47% | 3.75B | B- | ||
-22.61% | 2.92B | C | ||
+49.50% | 2.4B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TMCI Stock
- Ratings Treace Medical Concepts, Inc.